TARSUS PHARMACEUTICALS INC (TARS)

US87650L1035 - Common Stock

54.245  +1.34 (+2.52%)

Buy % Consensus

87

ChartMill assigns a Buy % Consensus number of 87% to TARS. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 66.3. This target is 22.22% above the current price.
TARS was analyzed by 15 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about TARS.
In the previous month the buy percentage consensus was at a similar level.
TARS was analyzed by 15 analysts, which is quite many. So the average rating should be quite meaningful.

Price Target & Forecast

Price Low Median Mean High 54.2541.4167.8366.3088.20 - -23.66% 25.04% 22.22% 62.60%
Up and Down Grades
Date Firm Action Rating
2024-11-15 Goldman Sachs Maintains Neutral -> Neutral
2024-11-14 Oppenheimer Maintains Outperform -> Outperform
2024-08-09 Oppenheimer Reiterate Outperform -> Outperform
2024-05-13 HC Wainwright & Co. Maintains Buy -> Buy
2024-05-10 Barclays Maintains Overweight -> Overweight
2024-05-09 Oppenheimer Maintains Outperform -> Outperform
2024-03-06 Jefferies Maintains Buy -> Buy
2024-02-29 Goldman Sachs Maintains Neutral -> Neutral
2024-02-28 Oppenheimer Reiterate Outperform -> Outperform
2024-02-28 Barclays Maintains Overweight -> Overweight
2024-02-28 HC Wainwright & Co. Maintains Buy -> Buy
2023-11-20 Goldman Sachs Initiate Neutral
2023-11-10 HC Wainwright & Co. Maintains Buy -> Buy
2023-09-11 Guggenheim Maintains Buy -> Buy
2023-08-14 Guggenheim Reiterate Buy -> Buy
2023-08-11 HC Wainwright & Co. Maintains Buy -> Buy
2023-07-26 HC Wainwright & Co. Maintains Buy -> Buy
2023-07-18 William Blair Initiate Outperform
2023-06-26 HC Wainwright & Co. Maintains Buy -> Buy
2023-06-16 Guggenheim Maintains Buy
2023-05-18 Guggenheim Initiate Buy
2023-05-08 Oppenheimer Reiterate Outperform
2023-03-15 HC Wainwright & Co. Reiterate Buy
2022-08-01 Barclays Initiate Overweight
2021-12-21 HC Wainwright & Co. Initiate Buy
2021-11-23 Oppenheimer Initiate Outperform
2021-10-08 Raymond James Maintains Strong Buy
2021-06-29 Raymond James Maintains Strong Buy